Analysis of Predictive Factors for Early Response to Ruxolitinib in 266 Patients with Myelofibrosis from the Polish Adult Leukemia Group (PALG) Registry
Joanna Góra‐Tybor, Krzysztof Jamroziak(Instytut Hematologii i Transfuzjologi), Magdalena Olszewska‐Szopa(Wroclaw Medical University), Ewa Bodzenta, Tomasz Sacha, Hubert Wysogląd(Jagiellonian University), Marek Hus(Medical University of Lublin), Krzysztof Lewandowski(Poznan University of Medical Sciences), Malwina Mazur(University of Rzeszów), Marta Sobas, Olga Grzybowska‐Izydorczyk, Joanna Niesiobędzka‐Krężel(Medical University of Warsaw), Waldemar Sawicki(National Academy of Medicine), Ilona Seferyńska, Maria Bieniaszewska(Gdańsk Medical University), Elżbieta Patkowska(Institute for Transfusion Medicine), Aleksandra Gołoś(Copernicus Memorial Hospital), Maria Czyżewska(Nicolaus Copernicus University), Agnieszka Michalska, Wojciech Świstek(University of Bydgoszcz)
Cited by 0
Related Papers
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries
|Leukemia|2015|258
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2024|162